GlycoMimetics Inc (GLYC) Opciones

GLYC Sold at .60 yesterday for 203% profit.

Next micro cap buyout or hostile take over will be BFRI interesting price action after hours FDA approved drug for AK skin cancer with late stage pipeline for Basil Cell and Squamous cell carcinoma Phase 3 and Acne Phase 2 call your dermatologist I bet they use Ameluz
the FDA also just green lighted 3 tubes can be used in a single session from 1 $400 a tube =$1200

https://www.biofrontera-us.com/research/product-pipeline

https://www.investing.com/news/company-news/biofrontera-locks-phase-3-sbcc-study-database-for-analysis-93CH-3662035


https://us.ameluz.com/
$GLYC

Bought some more GLYC this morning.

================

Biotech Up Over +100% Premarket Following Merger And Funding Announcement

Tuesday, October 29, 2024

A Maryland-based biotech company is already dominating Tuesday’s session prior to the opening bell after it was announced that the company will be merging with Crescent Biopharma and that it secured approximately $200 million in funding to financing operations through 2027, according to this morning’s release.

Traders were quick to snatch up shares of GlycoMimetics Inc. (Nasdaq:GLYC), with the current bid sitting at $0.3694/share (+119.62% implied open for sellers) at the time of writing. It should be an exciting session for this micro cap!

GlycoMimetics Inc is a clinical stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it plays in inflammation, cancer, and infection.

https://www.allpennystocks.com/specialreportsus/3692/biotech-up-over-100-premarket-following-merger-and-funding-announcement?utm_source=advfn

$GLYC

Renewed Opportunities!

My tons of GLYC shares at $0.17 now have Huge gains!!! Go, go, go!!!!!

Higher Peaks!

There is a lot of room.
Let's do it!

Up 200% 09:44 AM EDT, 10/29/2024 (MT Newswires) -- GlycoMimetics' (GLYC) shares climbed by more than 125% early Tuesday after saying it has agreed to be acquired by Crescent Biopharma, a privately held biotechnology company advancing a pipeline of oncology therapeutics.

glyc....................................https://stockcharts.com/h-sc/ui?s=glyc&p=W&b=5&g=0&id=p86431144783

Bankruptcy proceedings next. You been warned. Check out my latest post.

GLYC was $3.5 in Jan. Institutions and mutual funds holding 50 million shares at dollars, out of 64 million OS.

GLYC, Chief Medical Officer bought 310,000 shares at $0.26 at open market on June 21. He must know something.


https://www.otcmarkets.com/filing/html?id=17638385&guid=RXO-kWK48IECJth

GLYC: Article here ---
https://www.defenseworld.net/2024/06/25/glycomimetics-inc-nasdaqglyc-insider-edwin-rock-buys-190000-shares.html#google_vignette

you usually post the bottom charts before they go

Hitting .43s looking good

Delisting letter coming. You have been warned.

GLYC............................https://stockcharts.com/h-sc/ui?s=GLYC&p=W&b=5&g=0&id=p86431144783

Nice insider buys here = https://www.otcmarkets.com/filing/html?id=17638385&guid=NwO-kFXCNX90B3h

GLYC new low

Well? Good thing i held off on taking a position….

Gotta wait it out

Hopefully the FDA will give GLYC the the green light after reviewing phase 3 data in June

GLYC under $2

GLYC under $4

Dilution.

Reversal

Picked up a few heavy racks of shares under 2.95 today.


$GLYC

GLYC: Hey!!!! WHAT???? (HA-HA!!)

$GLYC: The chart is screaming bullflag breakout on 100day chart

Now at 2.50


Perfect BULL FLAG.


NICE


GO $GLYC

$GLYC Crazy runner here..on watch to see if it continues as insider bought a ton of shares..

https://stocktwits.com/soll/message/497100283

https://stockcharts.com/c-sc/sc?s=GLYC&p=D&b=5&g=0&i=0&r=1668953354914

THANKS!

yup and congrats on your other runner.

GO-GO-GO-GLYC!!!

PS: Hey, Girl, tap my latest POSTS behind @GRND --- what a SPECTACLE that one is!!!! (I grabbed their WARRANTS!!)

looking good here.

wow, new highs hitting right now!

and back to 2 bucks. lets see what tomorrow brings.

boing, and back up she goes.

manipulation bringing it …

..

down but lets see what happens.

here we go, breaking 2 bucks big time now.

its time to break 2 bucks and really move like it did in the past.

WOW WOW WOW CHIEF MEDICAL OFFICIER BOUGHT 200,000 SHARES $$$

he went from 0 shares to 200000 in two days. 2- 100000 shares buys 2 days

now 4 employees have bought shares.

WOOOOOOOOOOOOOOOOOW 63000 SHARE BUY $$$$$$$$$$$$$$$$

employees are buying toooooooooo

3 HUGE INSIDE BUYS BY 3 PEOPLE. 19K, 20K AND 25K $$$$$$$$$$$$$$$$

1.06/1.29 UP UP AND AWAY

Back to 99 cents.

Agreed. Things looking up. Load up while no one else wants it. ;)

Now is but time. The gap has filled, weak hands are out, corporate path is correct.

Depends at what level - if back to 2s first it’s a big loss till then

The Investment Case For GlycoMimetics
https://seekingalpha.com/article/4389595-investment-case-for-glycomimetics

News; $GLYC GlycoMimetics Program Data to be Highlighted Via Three Oral Presentations and Two Posters at 62nd American Society of Hematology Annual Meeting and Exposition

Data highlight the importance of early intervention with E-selectin inhibitors to disrupt inflammatory mechanisms driving acute vaso-occlusive crisis (VOC) in sickle cell disease (SCD) Additional presentations highlight multiple E-selectin inhibition strategies and their pot...

In case you are interested GLYC - GlycoMimetics Program Data to be Highlighted Via Three Oral Presentations and Two Posters at 62nd American Society of Hematology Annual Meeting and Exposition

Great buy at this price. I own a ton of it.

News; $GLYC New Pediatric and Secondary Endpoint Data from Rivipansel Phase 3 RESET Trial Presented at The Annual Scientific Conference on Sickle Cell and Thalassemia (ASCAT) Meeting

- Data highlight the importance of early intervention with fast-acting E-selectin inhibitors to disrupt the underlying inflammatory mechanisms driving acute vaso-occlusive crisis (VOC) - Abstracts for two of GlycoMimetics’ wholly-owned product candidates, rivipansel and...

In case you are interested GLYC - New Pediatric and Secondary Endpoint Data from Rivipansel Phase 3 RESET Trial Presented at The Annual Scientific Conference on Sickle Cell and Thalassemia (ASCAT) Meeting